Quantcast
Last updated on April 20, 2014 at 1:20 EDT

DrugRisk Alerts of Yaz Blood Clot Deaths As Bayer Continues Settlements

June 29, 2013

The DrugRisk Center is the web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com.

Chicago, IL (PRWEB) June 29, 2013

The birth control safety advocates at DrugRisk.com are announcing updated warnings for women who have taken the contraceptives Yaz or Yasmin. A recent report shows the drugs Yaz & Yasmin have been linked to 23 blood clot deaths in Canada, as Bayer continues to resolve injury claims in the United States*.

DrugRisk was created to improve the safety of patients taking popular prescription drugs by providing the latest research, safety alerts, recalls and litigation news. Visitors can find out if others have experienced similar side effects and determine if they need legal advice.

The resource center has added warnings from health experts like the British Medical Journal** and FDA*** that birth control pills containing the hormone drospirenone, such as Yaz and Yasmin, can increase the risk of blood clots.

Now, DrugRisk has learned that records from Health Canada allege a link between Yaz/Yasmin and 23 patient deaths from blood clots since 2007, as a judge there has certified a new Yaz class action lawsuit*.

So far, 9,961 patients have filed a Yaz lawsuit alleging side effects like blood clots in the United States, resulting in cases being consolidated to a special federal Multi-District Litigation court in Illinois (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois)).

DrugRisk has reported that Bayer spent nearly $1 billion so far to settle around 4,800 Yaz lawsuits alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT)****. They have also committed up to $1.5 billion to resolve all the cases*****.

Lawyers are still helping those who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin. Anyone affected is urged to contact the Drug Risk Center or speak with a lawyer about their legal options.

Due to the specialized nature of federal MDL litigation, patients should seek a lawyer with experience in defective drug litigation. DrugRisk only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*Vancouver Sun, 6/13/13; vancouversun.com/health/Yasmin+birth+control+pills+linked+deaths+Health+Canada+documents/8510364/story.html

**BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398

***FDA, 10/27/11, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf

****Bayer 2/28/13; annualreport2012.bayer.com/en/legal-risks.aspx

*****Reuters, 3/4/13; newsandinsight.thomsonreuters.com/Legal/News/2013/03_-_March/Bayer_reserves_$1_5_bln_to_cover_Yasmin,_Yaz_lawsuits/

For the original version on PRWeb visit: http://www.prweb.com/releases/2013-yaz-lawsuit-update/drugrisk-resource/prweb10882102.htm


Source: prweb